Phacilitate Leaders Forum

17th - 18th SEPTEMBER 2019



Magnus Jaderberg

Magnus Jaderberg

Chief Medical Officer, Head of Research & Development, Targovax AS

Qualified in medicine at Karolinska Institute, Stockholm, Sweden with 30 years in various pharmaceutical and biotech R&D functions including clinical research, pharmacovigilance, regulatory, strategic product development and general management. Held roles at national, European and global level while at Glaxo Smith Kline, Pharmacia, Wyeth and Bristol Myers Squibb. Therapeutic area expertise in infectious diseases and immune oncology. Supported the development and launch of Yervoy (ipilimumab), the first check point inhibitor in oncology. Now responsible for R&D of Oslo and Helsinki based immune oncology company with two technology platforms – adenovirus based gene therapy and RAS mutation peptides, both in phase II.

Honorary Lecturer in drug development at King’s College, London 2005 – 2010. Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom and the Royal Society of Medicine.

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd